Eli Lilly targets Scorpion Therapeutics to expand reach in oncology
After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotech’s current shareholders.
After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotech’s current shareholders.
What's Your Reaction?
